Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours Sep 2, 2008
CALGARY, Sept. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours ... About Oncolytics Biotech Inc. Oncolytics is a Calgary-based biotechnology... (PR Newswire)
Oncolytics Biotech Inc. Announces 2008 Second Quarter Results Jul 30, 2008
CALGARY, July 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced its financial results and highlights for the three and six month periods ended June 30, 2008 ... MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion and analysis should be read in conjunction with the unaudited interim consolidated financial statements of Oncolytics Biotech Inc. as at and for the three and six months ended June... (PR Newswire)
Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting May 30, 2008
ONCOLYTICS BIOTECH INC. ... CALGARY, May 30 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that two presentations covering preclinical work using the reovirus are scheduled to be delivered by Dr. Richard Vile of the Mayo College of Medicine, Rochester, Minnesota, at the American Society of Gene Therapy (ASGT) annual meeting in Boston, MA. The meeting runs from May 28 to June 1, 2008 ... About Oncolytics Biotech Inc. Oncolytics is a Calgary-based biotechnology company... (Canada Newswire)
Oncolytics Biotech Inc. Collaborators to Present Phase II Sarcoma Trial Results at ASCO Annual Meeting May 16, 2008
ONCOLYTICS BIOTECH INC. ... CALGARY, May 16 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that an abstract covering interim results of a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung is available on the American Society of Clinical Oncology (ASCO) website at and on the Oncolytics website at ... About Oncolytics Biotech Inc. Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as... (Canada Newswire)
Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy Feb 4, 2008
CALGARY, Feb. 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ('Oncolytics') reported today that Dr. Kevin Harrington and his research group at The Institute of Cancer Research, London, U.K. published the results of their work testing combination treatment schedules of reovirus and radiation in human and murine tumour cells in vitro and in vivo ... "The results of this preclinical research provided strong support for the combination REOLYSIN(R) and radiation clinical... (PR Newswire)
Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent Jan 29, 2008
ONCOLYTICS BIOTECH INC. ... CALGARY, Jan. 29 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") has been granted Canadian Patent 2,408,251 entitled "Clearance of Neoplastic Cells from Mixed Cellular Compositions using Viruses." The claims describe methods of selectively removing cancer cells ex vivo from blood stem cells and other organs using various viruses including modified vaccinia viruses, herpes simplex viruses, parapoxviruses and adenoviruses ... About Oncolytics... (Canada Newswire)
Oncolytics Biotech, Inc. announces publication of research Jan 8, 2008
CALGARY, AB, January 7, 2008 -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) (Oncolytics) reported today that a research group led by Dr. Richard Vile of the Mayo Clinic College of Medicine in Rochester, Minnesota, published the results of its work testing the antitumor efficacy and safety of various combinations of reovirus and cyclophosphamide in vivo ... About Oncolytics Biotech Inc.. (EurekAlert!)
Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference Nov 29, 2007
CALGARY, Nov. 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that Dr. Matt Coffey, Chief Scientific Officer of Oncolytics, is scheduled to deliver a presentation on Wednesday, December 5, 2007 entitled "Large Scale Production Process for the Oncolytic Agent REOLYSIN(R) (Human Reovirus)" at the Informa Life Sciences' 3rd Annual Vaccine Production Conference in Cologne, Germany ... About Oncolytics Biotech Inc. Oncolytics is a Calgary-based... (PR Newswire)
Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial Oct 24, 2007
CALGARY, Oct. 24 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that a poster presentation covering interim results from a U.K. Phase Ia/Ib combination REOLYSIN(R)/radiation clinical trial for patients with advanced or metastatic cancers is scheduled to be presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco ... About Oncolytics Biotech Inc. Oncolytics is a... (PR Newswire)
CNW Daybook for Tuesday, October 9, 2007 Oct 9, 2007
1250, Cell: (613) 391-2097 URL: TIME: 13:45 Eastern EVENT: TESCO CORPORATION PRESENTS AT THE NATIXIS BLEICHROEDER HIDDEN GEMS CONFERENCE INTERNET: Company's website CONTACT: Anthony Tripodo, (713) 359-7000, Tesco Corporation URL: TIME: 16:30 Eastern EVENT: VASOGEN THIRD QUARTER RESULTS INTERNET: PHONE NO.: (416) 641-6124, Toll free 1-866-300-4047 CONTACT: Glenn Neumann, Investor Relations, 2505 Meadowvale Blvd, tel: (905) 817-2004 URL:... (Canada Newswire)
Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials Sep 29, 2007
CALGARY, AB, --- September 28, 2007 - Oncolytics Biotech Inc. (Oncolytics) (TSX:ONC, NASDAQ:ONCY) announced that an oral presentation covering interim results from a U.K. Phase Ia/Ib combination REOLYSIN and radiation clinical trial for patients with advanced or metastatic cancers is scheduled to be presented at the National Cancer Research Institute (NCRI) conference on October 2, 2007 in Birmingham, U.K. The presentation, entitled Biological Approaches to Radiosensitisation: Viruses, Gene... (EurekAlert!)
Reovirus Infection of Melanoma Cells Generates Anti-Tumour Immunity Sep 12, 2007
Oncolytics Biotech Inc. Collaborators to Present Research at National Cancer Research Institute Conference CALGARY, Sept. 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that Dr. Robin Prestwich of CR-UK Clinical Centre, Leeds Institute of Molecular Medicine, University of Leeds, U.K. is scheduled to deliver a poster presentation on Tuesday, October 2, 2007 at the NCRI Cancer Conference entitled "Reovirus Infection of Human Melanoma Cells... (PR Newswire)
Business Sunflashes Jul 29, 2007
Oncolytics Biotech Inc. posted a $3. 7-million net loss in the second quarter, as the company continued to spend on developing a cancer treatment. (Canoe.ca)
Living Virus Destroys Cancer Cell: Novel Phase II Study For Sarcoma Begin Jul 27, 2007
The Cancer Therapy & Research Center Institute for Drug Development, in collaboration with Oncolytics Biotech Inc., a biotechnology company, has enrolled the first two patients in a new Phase II clinical study for patients with various types of sarcomas that have metastasized to the lung. CTRC is one of only three sites in the United States, and the only in Texas, enrolling patients. (Science Daily)
Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Paclitaxel and Carboplatin Trial May 29, 2007
CALGARY, May 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has commenced patient enrolment in its U.K. clinical trial to evaluate the anti-tumour effects of systemic administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced cancers including head and neck, melanoma, lung and ovarian ... About Oncolytics Biotech Inc. Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic... (PR Newswire)
Oncolytics Biotech Inc. Announces Issuance of 21th U.S. Patent May 29, 2007
ONCOLYTICS BIOTECH INC. ... CALGARY, May 29 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") has been granted U.S. Patent 7,223,585 entitled "Viral Purification Methods." The claims cover the production and purification of viruses including reovirus ... "We have now secured six U.S. patents relating to production or purification of viruses in addition to the various trade secrets relating to manufacture of our agent." About Oncolytics Biotech Inc. Oncolytics is a... (Canada Newswire)
U.S. NCI Files for Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R) May 14, 2007
CALGARY, May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the U.S. National Cancer Institute (NCI) has filed a protocol with the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial for patients with metastatic melanoma using systemic administration of REOLYSIN(R), Oncolytics' proprietary formulation of the human reovirus ... About Oncolytics Biotech Inc. Oncolytics is a Calgary-based biotechnology company focused... (PR Newswire)
Dealing Deadly Cancers A Knockout Punch May 11, 2007
Reovirus, a non-pathogenic virus under development at Calgary, Alberta-based Oncolytics Biotech, has shown powerful anti-cancer activity against cultured tumor cells, in animal models, and in human clinical trials ... Note: This story has been adapted from a news release issued by Oncolytics Biotech Inc.. (Science Daily)
Oncolytics Biotech Inc. Successfully Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) Apr 30, 2007
CALGARY, April 30 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has successfully completed initial scale up of its manufacturing process for REOLYSIN(R) ... About Oncolytics Biotech Inc. Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics ... SOURCE Oncolytics Biotech Inc.. (PR Newswire)
Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial Apr 25, 2007
CALGARY, AB, --- April 11, 2007 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that subsequent to the regulatory review period for this submission, it is proceeding with a Phase II trial to evaluate the intravenous administration of REOLYSIN in patients with various sarcomas that have metastasized to the lung ... About Oncolytics Biotech Inc.. (EurekAlert! -- Business News)
Oncolytics Biotech Inc., research collaborators demonstrate reovirus/gemcitabine Apr 18, 2007
CALGARY, AB, --- April 17, 2007 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announces that a poster by Dr. Maureen E. Lane et al. of Cornell University, New York, entitled "In Vivo Synergy between Oncolytic Reovirus and Gemcitabine in Ras-Mutated Human HCT116 Xenografts" is scheduled to be presented today at the American Association for Cancer Research (AACR) Annual Meeting in Los Angeles, CA. The meeting runs from April 14-18, 2007 ... About Oncolytics Biotech Inc.. (EurekAlert!)
Oncolytics Biotech Inc. Proceeds to Initiate U.S. Phase II Sarcoma Clinical Trial Apr 11, 2007
CALGARY, April 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that subsequent to the regulatory review period for this submission, it is proceeding with a Phase II trial to evaluate the intravenous administration of REOLYSIN(R) in patients with various sarcomas that have metastasized to the lung ... About Oncolytics Biotech Inc. Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as... (PR Newswire)
The multi-tasking reovirus Feb 8, 2007
In the past couple of years, researchers at Oncolytics Biotech have been developing a harmless virus as a potent cancer killer, but they have also been accumulating data that suggests in addition to directly killing tumor cells, the reovirus may prime the immune system to mount a separate, powerful and long lasting defence against cancer. Evidence for this theory has been mounting for the past year. (EurekAlert!)
Oncolytics Biotech Inc. Announces Public Offering Feb 6, 2007
CALGARY, Feb. 5 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC; NASDAQ:ONCY) announced today that it has filed a preliminary short form prospectus with Canadian securities regulators and a related registration statement with the U.S. Securities and Exchange Commission under the U.S.-Canada multi-jurisdictional disclosure system, relating to a proposed public offering of units ... SOURCE Oncolytics Biotech Inc.. (PR Newswire)
